pH Clinical Trials in Beijing, Beijing Municipality
256 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 256 trials
Recruiting
Phase 3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Merck Sharp & Dohme LLC1,200 enrolled196 locationsNCT06136559
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled167 locationsNCT06943872
Recruiting
Phase 1Phase 2
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Cervical CancerGastric/Gastroesophageal Junction AdenocarcinomaMicrosatellite Stable Colorectal Cancer
Bristol-Myers Squibb949 enrolled48 locationsNCT04895709
Recruiting
Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Genmab496 enrolled75 locationsNCT05283720
Recruiting
Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Advanced Gastric CancerMetastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung Cancer+4 more
BeiGene514 enrolled17 locationsNCT06585488
Recruiting
Phase 1Phase 2
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
TumorCardiovascular DiseasesPulmonary Fibrosis+3 more
Peking Union Medical College Hospital30 enrolled1 locationNCT07464132
Recruiting
Not Applicable
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic LeukemiaRefractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital353 enrolled1 locationNCT06343090
Recruiting
Phase 2
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
AbbVie110 enrolled31 locationsNCT02966756
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 2
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.100 enrolled15 locationsNCT07188610
Recruiting
Phase 1Phase 2
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
T-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia+1 more
Beijing GoBroad Hospital80 enrolled4 locationsNCT06316427
Recruiting
Phase 2
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Esophageal CancerGastric Cancer
Sichuan Baili Pharmaceutical Co., Ltd.376 enrolled1 locationNCT06008054
Recruiting
Phase 1
Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers
Schizophrenia
Vigonvita Life Sciences82 enrolled1 locationNCT06105151
Recruiting
Phase 1Phase 2
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Ascentage Pharma Group Inc.123 enrolled18 locationsNCT04494503
Recruiting
Phase 1Phase 2
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Peking University People's Hospital30 enrolled1 locationNCT06874946
Recruiting
Phase 2
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Chronic Myeloid LeukemiaAccelerated Phase CML
Shenzhen TargetRx Co., Ltd.40 enrolled1 locationNCT06453902
Recruiting
Phase 1Phase 2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Esophageal CancerStomach CancerStomach Cancer Recurrent+4 more
Essen Biotech75 enrolled1 locationNCT06532799
Recruiting
Phase 2
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaRelapsed Pediatric ALL
Chongqing Precision Biotech Co., Ltd100 enrolled10 locationsNCT05334823
Recruiting
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
Breast CancerLiver CancerColorectal, Cancer+10 more
Beijing Friendship Hospital2,700 enrolled4 locationsNCT06363123
Recruiting
Phase 2
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma
Beijing Tongren Hospital100 enrolled1 locationNCT06081478